Overview Fundamentals API Earnings EOD API Sample Code Pricing

EirGenix (6589 TWO) stock market data APIs

NT$85.8 -0.8(-0.9%) as of October 22, 2024
Price chart is built with Anychart

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.

EirGenix Financial Data Overview

86.6
85.8
-
87
84.8
72.2-111
26 475 M
306 M
1 134 M
-0.72
0.606
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '6589',
Type: 'Common Stock',
Name: 'EirGenix',
Exchange: 'TWO',
CurrencyCode: 'TWD',
CurrencyName: 'New Taiwan Dollar',
CurrencySymbol: 'NT$',
CountryName: 'Taiwan',
CountryISO: 'TW',
OpenFigi: NULL,
ISIN: 'TW0006589005',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

EirGenix Fundamental Data is available in our Financial Data APIs

  • Net Revenue 1 134 M
  • EBITDA -788 576 000
  • Earnings Per Share -2.75
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get EirGenix Earnings via APIs

  • Latest Release 2024-08-08
  • EPS/Forecast -0.42

Get EirGenix End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com